Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen
Abstract
Downloaded from http://aac.asm.org/ on April 14, 2021 by guest SUSCEPTIBILITY Identification of Antifungal Compounds against Multidrug- Resistant Candida auris Utilizing a High-Throughput Drug- Repurposing Screen a b a c b b b Yu-Shan Cheng, Jose Santinni Roma, Min Shen, Caroline Mota Fernandes, Patricia S. Tsang, He Eun Forbes, Helena Boshoff, c c,d,e a b Cristina Lazzarini, Maurizio Del Poeta, Wei Zheng, Peter R. Williamson National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, USA Veterans Affairs Medical Center, Northport, New York, USA ABSTRACT Candida auris is an emerging fatal fungal infection that has resulted in several outbreaks in hospitals and care facilities. Current treatment options are lim- ited by the development of drug resistance. Identification of new pharmaceuticals to combat these drug-resistant infections will thus be required to overcome this unmet medical need. We have established a bioluminescent ATP-based assay to identify new compounds and potential drug combinations showing effective growth